Dysmetabolic and neurological complications in leukemia patients treated with L-asparaginase.
D001215:Asparaginase / Q000009:adverse effects*; D002493:Central Nervous System Diseases / Q000139:chemically induced*; D002648:Child; D004796:Clinical Enzyme Tests; D004342:Drug Hypersensitivity / Q000209:etiology; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology / Q000652:urine; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008055:Lipids / Q000097:blood; D008297:Male; D008659:Metabolic Diseases / Q000139:chemically induced*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011517:Prothrombin Time; D014527:Uric Acid / Q000652:urine; D014839:Vomiting / Q000139:chemically induced
D008055:Lipids; D014527:Uric Acid; D005340:Fibrinogen; D001215:Asparaginase